<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Indomethacin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00328</strong>&#160; (APRD00109)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Indomethacin is a non-steroidal antiinflammatory agent (<span class="caps">NSAIA</span>) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (<span class="caps">COX</span>), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00328/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00328/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00328.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00328.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00328.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00328.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00328.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00328">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Indometacin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Arthrexin</td><td>Alphapharm</td></tr><tr><td>Elmetacin</td><td>Sankyo</td></tr><tr><td>Indaflex</td><td>Andromaco</td></tr><tr><td>Indocid</td><td>Lundbeck</td></tr><tr><td>Indocin</td><td>Lundbeck</td></tr><tr><td>Indolar SR</td><td>Sandoz</td></tr><tr><td>Indomed</td><td>Greater Pharma</td></tr><tr><td>Indoxen</td><td>Quality Pharmaceutical</td></tr><tr><td>Metindol</td><td>GlaxoSmithKline</td></tr><tr><td>Mikametan</td><td>Mikasa Seiyaku</td></tr><tr><td>Nu-Indo</td><td>Nu-Pharm</td></tr><tr><td>Reumacide</td><td>Vit&#243;ria</td></tr><tr><td>Tivorbex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/gout-suppressants">Gout Suppressants</a></li>
<li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li>
<li><a href="/mesh/cardiovascular-agents">Cardiovascular Agents</a></li>
<li><a href="/mesh/tocolytic-agents">Tocolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>53-86-1</td></tr><tr><th>Weight</th><td>Average: 357.788<br>Monoisotopic: 357.076785712</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>16</sub>ClNO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>CGIGDMFJXJATDK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00328.gif?1265922771">show</a>(7.7 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Benzoylindoles</td></tr><tr><th>Direct parent</th><td>Benzoylindoles</td></tr><tr><th>Alternative parents</th><td>Indole-3-acetic Acid Derivatives; Indolecarboxylic Acids and Derivatives; Benzamides; Indoles; Benzoyl Derivatives; Anisoles; Alkyl Aryl Ethers; Chlorobenzenes; N-substituted Pyrroles; Aryl Chlorides; Carboxylic Acids; Enolates; Polyamines; Carboxylic Acid Amides; Organochlorides</td></tr><tr><th>Substituents</th><td>indole-3-acetic acid derivative; indolecarboxylic acid derivative; indolyl carboxylic acid derivative; benzamide; indole; benzoyl; anisole; phenol ether; alkyl aryl ether; chlorobenzene; aryl chloride; aryl halide; n-substituted pyrrole; substituted pyrrole; benzene; pyrrole; carboxamide group; polyamine; carboxylic acid; carboxylic acid derivative; ether; enolate; amine; organochloride; organohalogen; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moeity through the acyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.</td></tr><tr><th>Pharmacodynamics</th><td>Indomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.</td></tr><tr><th>Mechanism of action</th><td>Indomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.</td></tr><tr><th>Absorption</th><td>Bioavailability is approximately 100% following oral administration and 80&#8211;90% following rectal administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Indomethacin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00156"><i>O</i>-Desmethylindomethacin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/156">Details</a></td></tr><tr><td>Indomethacin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003541" target="_blank">UDP-glucuronosyltransferase 1-1</a></li></ul></td><td><a href="/metabolites/DBMET00157">Indomethacin acyl glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/157">Details</a></td></tr><tr><td>Indomethacin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002705" target="_blank">Liver carboxylesterase 1</a></li></ul></td><td><a href="/metabolites/DBMET00158"><i>N</i>-Deschlorobenzoyl indomethacin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/158">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00158"><i>N</i>-Deschlorobenzoyl indomethacin</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01351"><i>O</i>-Desmethyl-<i>N</i>-deschlorobenzoyl indomethacin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1535">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion.</td></tr><tr><th>Half life</th><td>4.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD<sub>50</sub> of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Indomethacin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9509</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5857</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.636</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9313</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.834</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8334</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.712</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6436</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9302</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6978</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8728
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9743
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          4.0722 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9818
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8306
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Iroko pharmaceuticals llc</li>
<li>Sandoz inc</li>
<li>Able laboratories inc</li>
<li>Avanthi inc</li>
<li>Inwood laboratories inc sub forest laboratories inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Halsey drug co inc</li>
<li>Heritage pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Parke davis div warner lambert co</li>
<li>Pioneer pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Roxane laboratories inc</li>
<li>Superpharm corp</li>
<li>Vintage pharmaceuticals llc</li>
<li>Watson laboratories inc</li>
<li>App pharmaceuticals llc</li>
<li>G and w laboratories inc</li>
<li>Lundbeck inc</li>
<li>Bedford laboratories div ben venue laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li>Apothecary Shop Wholesale</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.endo.com">Endo Pharmaceuticals Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.gwlabs.com">G &amp; W Labs</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.inwoodlabs.com">Inwood Labs</a></li>
<li><a href="http://www.iroko.com">Iroko Pharmaceuticals</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.kvktech.com">KVK-Tech Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patientfirst.com">Patient First Corp.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li>Prescription Dispensing Service Inc.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li>Talbert Medical Management Corp.</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Veratex Corp.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>25 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>50 mg</td></tr><tr><td>Capsule, extended release</td><td>Oral</td><td>75 mg</td></tr><tr><td>Injection</td><td>Intravenous</td><td>1 mg</td></tr><tr><td>Suppository</td><td>Rectal</td><td>100 mg</td></tr><tr><td>Suppository</td><td>Rectal</td><td>50 mg</td></tr><tr><td>Suspension</td><td>Oral</td><td>25 mg/5 ml</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00630">Alendronate</a></td><td>Increased risk of gastric toxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The NSAID, indomethacin, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Nonsteroidal Anti-Inflammatory Agents such as indomethacin may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. </td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00887">Bumetanide</a></td><td>The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide.</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Monitor for nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00861">Diflunisal</a></td><td>Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure).</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Indomethacin via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00903">Ethacrynic acid</a></td><td>The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid.</td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.</td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>Indomethacin decreases the effect of losartan</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB06813">Pralatrexate</a></td><td>NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. </td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Probenecid increases the effect/toxicity of indomethacin</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Risk of acute renal impairment with this combination</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed.	</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food or antacids to reduce irritation.</li></ul></td></tr></tbody></table>